Stuart Viegas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Stuart Viegas has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Alexander N. Comninos
Imperial College London
1 shared publication - Ali Abbara
Section of Endocrinology and Investigative Medicine, Imperial College London , London W12 0NN
1 shared publication Catherine Nelson-Piercy
Imperial College Healthcare NHS Trust, London, UK
1 shared publication- Christopher Lord
Imaging Department, Imperial College Healthcare NHS Trust, St Mary's Hospital, London, W2 1NY, United Kingdom
1 shared publication - Dimitri Amiras
Imaging Department, Imperial College Healthcare NHS Trust, London, UK
1 shared publication - Monica Bawor
Department of Medicine, Imperial College Healthcare NHS Trust, Fulham Palace Road, London, UK, W68RF
1 shared publication
Latest Publications
- Open Access
- 20 June 2025
- Published by Springer Nature in Skeletal Radiology
- Vol. 54 (12) , 2597-2606
Recognising serous atrophy of bone marrow: a review of imaging findings
Serous atrophy of bone marrow (SABM) is a rare bone marrow disorder associated with severe illness and poor nutritional state. This results in characteristic MRI signal alterations of the bone marrow and surrounding soft tissues. The unusual imaging features are often misinterpreted as technical error or erroneously attributed to underlying malignancy, resulting in unnecessary additional imaging. Therefore, it is important to differentiate SABM from technical failures and other infiltrating marrow processes. This review provides an overview of the imaging characteristics of SABM and associated imaging pitfalls, based on examples from our own practice.
- 20 June 2025
- Published by Springer Nature in Skeletal Radiology
- Vol. 54 (12) , 2597-2606
Open AccessRecognising serous atrophy of bone marrow: a review of imaging findings
Serous atrophy of bone marrow (SABM) is a rare bone marrow disorder associated with severe illness and poor nutritional state. This results in characteristic MRI signal alterations of the bone marrow and surrounding soft tissues. The unusual imaging features are often misinterpreted as technical error or erroneously attributed to underlying malignancy, resulting in unnecessary additional imaging. Therefore, it is important to differentiate SABM from technical failures and other infiltrating marrow processes. This review provides an overview of the imaging characteristics of SABM and associated imaging pitfalls, based on examples from our own practice.
- Open Access
Rhabdomyolysis after COVID-19 Infection: A Case Report and Review of the Literature
Rhabdomyolysis is a condition in which muscle breaks down potentially leading to renal dysfunction, and often occurs secondary to a precipitating factor. Viral or bacterial infections are common precipitants for initiating rhabdomyolysis. Recently, healthcare systems across the world have been challenged by a pandemic of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causing ‘coronavirus disease 2019’ (COVID-19) disease. SARS-CoV-2 infection is recognized to cause respiratory and cardiovascular compromise, thromboembolic events, and acute kidney injury (AKI); however, it is not known whether it can precipitate rhabdomyolysis, with only a limited number of cases of SARS-CoV-2 infection preceding rhabdomyolysis reported to date. Here, we report the case of a 64-year-old woman who developed rhabdomyolysis shortly after SARS-CoV-2 infection and COVID-19. She initially presented with muscular pain, a creatine kinase level of 119,301 IU/L, and a mild rise in her creatinine level to 92 µmol/L, but successfully recovered with intravenous fluid support. We also review the literature to summarise previously reported cases of rhabdomyolysis precipitated by SARS-CoV-2, highlighting the need to consider this diagnosis in patients presenting with SARS-CoV-2 and myalgia.
Open AccessRhabdomyolysis after COVID-19 Infection: A Case Report and Review of the Literature
Rhabdomyolysis is a condition in which muscle breaks down potentially leading to renal dysfunction, and often occurs secondary to a precipitating factor. Viral or bacterial infections are common precipitants for initiating rhabdomyolysis. Recently, healthcare systems across the world have been challenged by a pandemic of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causing ‘coronavirus disease 2019’ (COVID-19) disease. SARS-CoV-2 infection is recognized to cause respiratory and cardiovascular compromise, thromboembolic events, and acute kidney injury (AKI); however, it is not known whether it can precipitate rhabdomyolysis, with only a limited number of cases of SARS-CoV-2 infection preceding rhabdomyolysis reported to date. Here, we report the case of a 64-year-old woman who developed rhabdomyolysis shortly after SARS-CoV-2 infection and COVID-19. She initially presented with muscular pain, a creatine kinase level of 119,301 IU/L, and a mild rise in her creatinine level to 92 µmol/L, but successfully recovered with intravenous fluid support. We also review the literature to summarise previously reported cases of rhabdomyolysis precipitated by SARS-CoV-2, highlighting the need to consider this diagnosis in patients presenting with SARS-CoV-2 and myalgia.
- 12 April 2019
- Published by BMJ in Practical Neurology
- Vol. 19 (5) , 444-446
Difficult case: rituximab in anti-SRP antibody myositis in pregnancy
A 30-year-old nulliparous woman presented at 15-week gestation with severe skeletal and respiratory muscle weakness, having been diagnosed with anti-signal recognition particle antibody myositis 3 years before. Remission had previously been induced with rituximab (after failure of standard therapies). She had continued oral prednisolone and rituximab every 6 months but had stopped this when planning pregnancy. At 16-weeks gestation, she restarted corticosteroids and rituximab, with clinical and biochemical recovery and no complications. Rituximab should ideally be given in the first trimester; treatment later in pregnancy increases the risk of neonatal B-cell depletion and cytopenias. The fetal risk from drug therapy must be weighed against the risk to mother and fetus from untreated disease. This report highlights the importance of preconception counselling for disease control and patient education regarding medication safety and early referral to obstetric medicine clinics, to facilitate complex clinical decision-making.
- 12 April 2019
- Published by BMJ in Practical Neurology
- Vol. 19 (5) , 444-446
Difficult case: rituximab in anti-SRP antibody myositis in pregnancy
A 30-year-old nulliparous woman presented at 15-week gestation with severe skeletal and respiratory muscle weakness, having been diagnosed with anti-signal recognition particle antibody myositis 3 years before. Remission had previously been induced with rituximab (after failure of standard therapies). She had continued oral prednisolone and rituximab every 6 months but had stopped this when planning pregnancy. At 16-weeks gestation, she restarted corticosteroids and rituximab, with clinical and biochemical recovery and no complications. Rituximab should ideally be given in the first trimester; treatment later in pregnancy increases the risk of neonatal B-cell depletion and cytopenias. The fetal risk from drug therapy must be weighed against the risk to mother and fetus from untreated disease. This report highlights the importance of preconception counselling for disease control and patient education regarding medication safety and early referral to obstetric medicine clinics, to facilitate complex clinical decision-making.